U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07209462) titled 'Phase 2 Study of MRM-3379 in Male Participants With Fragile X Syndrome' on Oct. 02.
Brief Summary: This study is a multicenter, double-blind, randomized, placebo-controlled study to assess the safety and tolerability of 3 doses of MRM-3379 in male participants with Fragile X Syndrome ages 16 to 45 (inclusive). In addition, a parallel cohort of participants ages 13 to <16 will receive open-label MRM-3379. All participants will participate for 12 weeks of treatment. The study is also intended as a proof-of-concept investigation to evaluate whether MRM-3379 can improve FXS symptoms
Study Start Date: Dec., 2025
Study Type: INTERVENTION...